BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, Liberopoulos EN. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clin Ther. 2010;32:492-505. [PMID: 20399986 DOI: 10.1016/j.clinthera.2010.03.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Rizos CV, Liberopoulos EN, Tellis CC, Tselepis AD, Elisaf MS. The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-γ activating capacity on plasma 8-isoprostane prostaglandin F2a levels. Arch Med Sci 2013;9:172-6. [PMID: 23515108 DOI: 10.5114/aoms.2013.33357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
2 Cho KI, Kim BH, Park YH, Ahn J, Kim SH, Chung WJ, Kim W, Sohn IS, Shin JH, Kim YJ, Chang K, Yu CW, Ahn SH, Kim SY, Ryu JK, Lee JY, Hong BK, Hong TJ, Gyu Park C. Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study. Clinical Therapeutics 2019;41:1508-21. [DOI: 10.1016/j.clinthera.2019.05.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
3 Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RA. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes Metab Syndr Obes 2018;11:427-38. [PMID: 30174450 DOI: 10.2147/DMSO.S171365] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
4 Rizos CV, Kostapanos MS, Rizos EC, Tselepis AD, Elisaf MS. The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose. J Cardiovasc Pharmacol Ther 2015;20:276-83. [DOI: 10.1177/1074248414549419] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
5 El-Lakkany NM, Seif El-Din SH, Sabra AA, Hammam OA, Ebeid FA. Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver. Res Pharm Sci 2016;11:374-82. [PMID: 27920819 DOI: 10.4103/1735-5362.192487] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
6 Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014;6:517-30. [PMID: 25068013 DOI: 10.4330/wjc.v6.i7.517] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
7 Fraulob JC, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond). 2012;123:259-270. [PMID: 22420611 DOI: 10.1042/cs20110373] [Cited by in Crossref: 48] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
8 Rizos CV. Manidipine: A different dihydropyridine. WJH 2011;1:3. [DOI: 10.5494/wjh.v1.i1.3] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
9 Pushpakom S, Kolamunnage-Dona R, Taylor C, Foster T, Spowart C, García-Fiñana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M; TAILoR Study Group. TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clin Infect Dis 2020;70:2062-72. [PMID: 31425580 DOI: 10.1093/cid/ciz589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
10 Rizos CV, Elisaf MS. Telmisartan: a multifaceted antihypertension drug. Curr Med Res Opin 2016;32:1397-8. [PMID: 27052942 DOI: 10.1080/03007995.2016.1176015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Son M, Kim Y, Lee D, Roh H, Son H, Guk J, Jang SB, Nam SY, Park K. Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study. Clin Ther 2014;36:1147-58. [PMID: 24998012 DOI: 10.1016/j.clinthera.2014.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
12 Liberopoulos EN, Moutzouri E, Rizos CV, Barkas F, Liamis G, Elisaf MS. Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia. J Cardiovasc Pharmacol Ther. 2013;18:113-118. [PMID: 23113965 DOI: 10.1177/1074248412463611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Neto-Ferreira R, Rocha VN, Souza-Mello V, Mandarim-de-Lacerda CA, de Carvalho JJ. Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol Metab Syndr. 2013;5:32. [PMID: 23816341 DOI: 10.1186/1758-5996-5-32] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
14 Wang Y, Qiao S, Han D, Rong X, Wang Y, Xue J, Yang J. Telmisartan Improves Insulin Resistance: A Meta-Analysis. American Journal of Therapeutics 2018;25:e642-51. [DOI: 10.1097/mjt.0000000000000733] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Pushpakom SP, Taylor C, Kolamunnage-Dona R, Spowart C, Vora J, García-Fiñana M, Kemp GJ, Whitehead J, Jaki T, Khoo S, Williamson P, Pirmohamed M. Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. BMJ Open 2015;5:e009566. [PMID: 26474943 DOI: 10.1136/bmjopen-2015-009566] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
16 Takagi H, Umemoto T; All-Literature Investigation of Cardiovascular Evidence Group. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. J Am Soc Hypertens 2014;8:578-92. [PMID: 25151319 DOI: 10.1016/j.jash.2014.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
17 Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T. Effects of telmisartan on C-reactive protein levels: A meta-analysis of randomized controlled trials. International Journal of Cardiology 2012;156:238-41. [DOI: 10.1016/j.ijcard.2012.01.104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Takagi H, Umemoto T. Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials. Int J Cardiol 2012;157:403-7. [PMID: 22386702 DOI: 10.1016/j.ijcard.2012.02.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
19 Takagi H, Mizuno Y, Goto S, Umemoto T. Overview of telmisartan for blood pressure reduction among angiotensin II receptor blockers: A meta-analysis of head-to-head randomized trials. International Journal of Cardiology 2013;167:3051-6. [DOI: 10.1016/j.ijcard.2012.11.086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Rizos CV, Liberopoulos EN, Tellis CC, Florentin M, Elisaf MS, Tselepis AD. Combining Rosuvastatin with Sartans of Different Peroxisome Proliferator-Activated Receptor-γ Activating Capacity Is Not Associated with Different Changes in Low-Density Lipoprotein Subfractions and Plasma Lipoprotein-Associated Phospholipase A 2. Metabolic Syndrome and Related Disorders 2011;9:217-23. [DOI: 10.1089/met.2010.0120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Crowley MJ, Powers BJ, Myers ER, Mcbroom AJ, Sanders GD. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization. American Heart Journal 2012;163:777-782.e8. [DOI: 10.1016/j.ahj.2012.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
22 Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, Elisaf M. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance: Lipid-lowering treatment and glucose. International Journal of Clinical Practice 2011;65:1141-8. [DOI: 10.1111/j.1742-1241.2011.02779.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
23 Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother 2010;11:2635-50. [PMID: 20497095 DOI: 10.1517/14656566.2010.491512] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
24 Takagi H, Umemoto T. Telmisartan improves insulin sensitivity: A meta-analysis of randomized head-to-head trials. International Journal of Cardiology 2012;156:92-6. [DOI: 10.1016/j.ijcard.2011.11.070] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
25 Zhou MS, Schulman IH, Zeng Q. Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease. Vasc Med. 2012;17:330-341. [PMID: 22814999 DOI: 10.1177/1358863x12450094] [Cited by in Crossref: 58] [Cited by in F6Publishing: 21] [Article Influence: 6.4] [Reference Citation Analysis]
26 Tsoi B, Akioyamen LE, Bonner A, Frankfurter C, Levine M, Pullenayegum E, Goeree R, O'Reilly D. Comparative Efficacy of Angiotensin II Antagonists in Essential Hypertension: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. Heart Lung Circ 2018;27:666-82. [PMID: 28807582 DOI: 10.1016/j.hlc.2017.06.721] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Bellos I, Pergialiotis V, Perrea DN. Comparative efficacy of fixed-dose statin and antihypertensive agent combinations: A network meta-analysis of randomized controlled trials. Vascul Pharmacol 2021;:106900. [PMID: 34343694 DOI: 10.1016/j.vph.2021.106900] [Reference Citation Analysis]
28 Kakuta H, Kurosaki E, Niimi T, Gato K, Kawasaki Y, Suwa A, Honbou K, Yamaguchi T, Okumura H, Sanagi M, Tomura Y, Orita M, Yonemoto T, Masuzaki H. Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses. J Pharmacol Exp Ther 2014;349:10-20. [DOI: 10.1124/jpet.113.211722] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]